<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01283542</url>
  </required_header>
  <id_info>
    <org_study_id>CSOM230D2401</org_study_id>
    <nct_id>NCT01283542</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.</brief_title>
  <acronym>Passion I</acronym>
  <official_title>An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assessed pasireotide LAR efficacy on patients with non-functioning pituitary
      adenomas concerning tumor growth.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 26, 2012</start_date>
  <completion_date type="Actual">September 12, 2017</completion_date>
  <primary_completion_date type="Actual">September 12, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Non-functioning Pituitary Adenomas (NFPA) Who Achieve Tumor Volume Reduction of at Least 20% After 24 Weeks (FAS)</measure>
    <time_frame>Baseline up to 24 weeks</time_frame>
    <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility.The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor. A change ≥ 20% in the original volume of the tumor was considered to be clinically significant. Evaluable participants required tumor volume assessment at baseline and at week 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Volume Main Phase (FAS)</measure>
    <time_frame>baseline to week 4, 12, 24</time_frame>
    <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Volume in Extension Phase (FAS)</measure>
    <time_frame>baseline to week 48, 72, 96</time_frame>
    <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Volume Change From Baseline in Main Phase (FAS)</measure>
    <time_frame>baseline to week 4, 12, 24</time_frame>
    <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Volume Change From Baseline in Extension Phase (FAS)</measure>
    <time_frame>baseline to week 48, 72, 96</time_frame>
    <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Volume Percent Change From Baseline in Main Phase (FAS)</measure>
    <time_frame>baseline to week 4, 12, 24</time_frame>
    <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Volume Percent Change From Baseline in Extension Phase (FAS)</measure>
    <time_frame>baseline to week 48, 72, 96</time_frame>
    <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Tumour Volume Reduction in Main Phase (FAS)</measure>
    <time_frame>baseline to week 4, 12, 24</time_frame>
    <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Tumour Volume Reduction of at Least ≥ 20% in Main Phase (FAS)</measure>
    <time_frame>baseline to week 4, 12, 24</time_frame>
    <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Tumour Volume Reduction in Extension Phase (FAS)</measure>
    <time_frame>baseline to week 48, 72, 96</time_frame>
    <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Tumour Volume Reduction of at Least ≥ 20% in Extension Phase (FAS)</measure>
    <time_frame>baseline to week 48, 72, 96</time_frame>
    <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Absence and Presence of Relevant Disease-related Symptoms (FAS)</measure>
    <time_frame>Baseline and at weeks 4, 12,24,48,72, 96</time_frame>
    <description>The absence and presence of disease-related symptoms were reported by patients and recorded by the medical staff. Patients classified the symptoms according to a 5-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean GH and IGF-1 Hormone Levels During Main and Extension Phases (FAS)</measure>
    <time_frame>Baseline and at weeks 24, 48, 96</time_frame>
    <description>Hormone levels, including those of GH, IGF-1, and prolactin were evaluated by a central lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean ACTH and Estradiol Hormone Levels During Main and Extension Phases (FAS)</measure>
    <time_frame>Baseline and at weeks 24, 48, 96</time_frame>
    <description>Hormone levels, including those of growth hormone (GH),insulin-like growth factor 1 (IGF-1), follicle-stimulating hormone (FSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), prolactin, cortisol, free thyroxine (free T4), and estradiol (for women) or testosterone (for men), were evaluated by a central lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Cortisol Hormone Levels During Main and Extension Phases (FAS)</measure>
    <time_frame>Baseline and at weeks 24, 48, 96</time_frame>
    <description>Hormone levels, including those of GH, IGF-1, follicle-stimulating hormone (FSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), prolactin, cortisol, free T4, and estradiol (for women) or testosterone (for men), were evaluated by a central lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean LH and FSH Hormone Levels During Main and Extension Phases (FAS)</measure>
    <time_frame>Baseline and at weeks 24, 48, 96</time_frame>
    <description>Hormone levels, including those of GH, IGF-1, follicle-stimulating hormone (FSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), prolactin, cortisol, free T4, and estradiol (for women) or testosterone (for men), were evaluated by a central lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Testosterone and Free T4 Hormone Levels During Main and Extension Phases (FAS)</measure>
    <time_frame>Baseline and at weeks 24, 48, 96</time_frame>
    <description>Hormone levels, including those of GH, IGF-1, follicle-stimulating hormone (FSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), prolactin, cortisol, free T4, and estradiol (for women) or testosterone (for men), were evaluated by a central lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean TSH Hormone Levels During Main and Extension Phases (FAS)</measure>
    <time_frame>Baseline and at weeks 24, 48, 96</time_frame>
    <description>Hormone levels, including those of GH, IGF-1, follicle-stimulating hormone (FSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), prolactin, cortisol, free T4, and estradiol (for women) or testosterone (for men), were evaluated by a central lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Alpha Subunit Levels in Main and Extension Phases (FAS)</measure>
    <time_frame>Baseline and at weeks 12,24,48,72, 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Reduction From Baseline of Alpha Subunit ≥50% in Main and Extension Phases (FAS)</measure>
    <time_frame>Baseline up to approximately Week 96</time_frame>
    <description>Alpha subunit levels were determined at a central laboratory.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Non-functioning Pituitary Adenoma</condition>
  <arm_group>
    <arm_group_label>Pasireotide LAR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pasireotide LAR</intervention_name>
    <description>20 and 40 mg of powder in vials and 2 mL of vehicle in ampoules (for reconstitution) administered as a depot intragluteal IM (intramuscular) injection</description>
    <arm_group_label>Pasireotide LAR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-functioning pituitary adenoma ≥ 1cm, patients without any previous treatment for
             the tumor

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

        Exclusion Criteria:

          -  Patients who required a surgical intervention for relief of any sign or symptom
             associated with tumor compression

          -  Previous pituitary surgery

          -  Previous medical treatment for pituitary tumor

          -  Patients who had received pituitary irradiation within 10 years prior to randomization

          -  Prolactin (PRL) levels &gt; 100 ng/mL. PRL evaluation should have been performed with
             diluted samples to ensure &quot;hook effect.&quot; was avoided

          -  Patients who presented prolactinomas, acromegaly or Cushing's disease

          -  Patients with compression of the optic chiasm causing acute clinically significant
             visual field defects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fortaleza</city>
        <state>CE</state>
        <zip>04636-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80030-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21941-913</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Joinville</city>
        <state>SC</state>
        <zip>89201260</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Botucatu</city>
        <state>SP</state>
        <zip>18618-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04023-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403 000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 17, 2010</study_first_submitted>
  <study_first_submitted_qc>January 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2011</study_first_posted>
  <results_first_submitted>September 12, 2018</results_first_submitted>
  <results_first_submitted_qc>April 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2019</results_first_posted>
  <last_update_submitted>April 24, 2019</last_update_submitted>
  <last_update_submitted_qc>April 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-functioning pituitary adenoma,</keyword>
  <keyword>pasireotide LAR,</keyword>
  <keyword>tumor volume</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Pituitary Neoplasms</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pasireotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 26, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT01283542/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT01283542/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Twenty seven patients were screened and 21 met eligibility requirements.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pasireotide LAR</title>
          <description>All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Acute or progressive vision loss</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Uncontrolled diabetes mellitus</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>abnormal laboratory values</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline participants met eligibility requirements and received at least 1 dose of study medication</population>
      <group_list>
        <group group_id="B1">
          <title>Pasireotide LAR</title>
          <description>All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.65" spread="11.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White/Caucasian ancestry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African ancestry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian ancestry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.95" spread="4.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Non-functioning Pituitary Adenomas (NFPA) Who Achieve Tumor Volume Reduction of at Least 20% After 24 Weeks (FAS)</title>
        <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility.The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor. A change ≥ 20% in the original volume of the tumor was considered to be clinically significant. Evaluable participants required tumor volume assessment at baseline and at week 24.</description>
        <time_frame>Baseline up to 24 weeks</time_frame>
        <population>Evaluable participants required tumor volume assessment at baseline and at week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR</title>
            <description>All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Non-functioning Pituitary Adenomas (NFPA) Who Achieve Tumor Volume Reduction of at Least 20% After 24 Weeks (FAS)</title>
          <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility.The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor. A change ≥ 20% in the original volume of the tumor was considered to be clinically significant. Evaluable participants required tumor volume assessment at baseline and at week 24.</description>
          <population>Evaluable participants required tumor volume assessment at baseline and at week 24</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="2.1" upper_limit="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Volume Main Phase (FAS)</title>
        <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
        <time_frame>baseline to week 4, 12, 24</time_frame>
        <population>number of participants with evaluable data varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR</title>
            <description>All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Volume Main Phase (FAS)</title>
          <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
          <population>number of participants with evaluable data varied across visits</population>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Main Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97" spread="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Main Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.31" spread="6.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Main Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.31" spread="6.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Main Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" spread="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Volume in Extension Phase (FAS)</title>
        <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
        <time_frame>baseline to week 48, 72, 96</time_frame>
        <population>number of participants with evaluable data varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR</title>
            <description>All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Volume in Extension Phase (FAS)</title>
          <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
          <population>number of participants with evaluable data varied across visits</population>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extension Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" spread="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Volume Change From Baseline in Main Phase (FAS)</title>
        <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
        <time_frame>baseline to week 4, 12, 24</time_frame>
        <population>number of participants with evaluable data varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR</title>
            <description>All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Volume Change From Baseline in Main Phase (FAS)</title>
          <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
          <population>number of participants with evaluable data varied across visits</population>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Main Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="-1.70" upper_limit="4.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Main Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="-0.45" upper_limit="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Main Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" lower_limit="-1.24" upper_limit="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Volume Change From Baseline in Extension Phase (FAS)</title>
        <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
        <time_frame>baseline to week 48, 72, 96</time_frame>
        <population>number of participants with evaluable data varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR</title>
            <description>All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Volume Change From Baseline in Extension Phase (FAS)</title>
          <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
          <population>number of participants with evaluable data varied across visits</population>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extension Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Volume Percent Change From Baseline in Main Phase (FAS)</title>
        <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
        <time_frame>baseline to week 4, 12, 24</time_frame>
        <population>number of participants with evaluable data varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR</title>
            <description>All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Volume Percent Change From Baseline in Main Phase (FAS)</title>
          <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
          <population>number of participants with evaluable data varied across visits</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Main Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.92" lower_limit="-52.11" upper_limit="125.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Main Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.36" lower_limit="-42.19" upper_limit="120.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Main Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.98" lower_limit="-32.79" upper_limit="48.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Volume Percent Change From Baseline in Extension Phase (FAS)</title>
        <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
        <time_frame>baseline to week 48, 72, 96</time_frame>
        <population>number of participants with evaluable data varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR</title>
            <description>All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Volume Percent Change From Baseline in Extension Phase (FAS)</title>
          <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
          <population>number of participants with evaluable data varied across visits</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extension Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.83" spread="67.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.57" spread="14.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.59" spread="53.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Tumour Volume Reduction in Main Phase (FAS)</title>
        <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
        <time_frame>baseline to week 4, 12, 24</time_frame>
        <population>number of participants with evaluable data varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR</title>
            <description>All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Tumour Volume Reduction in Main Phase (FAS)</title>
          <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
          <population>number of participants with evaluable data varied across visits</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Tumour Volume Reduction of at Least ≥ 20% in Main Phase (FAS)</title>
        <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
        <time_frame>baseline to week 4, 12, 24</time_frame>
        <population>number of participants with evaluable data varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR</title>
            <description>All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Tumour Volume Reduction of at Least ≥ 20% in Main Phase (FAS)</title>
          <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
          <population>number of participants with evaluable data varied across visits</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Main Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="1.3" upper_limit="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Main Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="0.1" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Main Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="2.1" upper_limit="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Tumour Volume Reduction in Extension Phase (FAS)</title>
        <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
        <time_frame>baseline to week 48, 72, 96</time_frame>
        <population>number of participants with evaluable data varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR</title>
            <description>All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Tumour Volume Reduction in Extension Phase (FAS)</title>
          <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
          <population>number of participants with evaluable data varied across visits</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extension Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Tumour Volume Reduction of at Least ≥ 20% in Extension Phase (FAS)</title>
        <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
        <time_frame>baseline to week 48, 72, 96</time_frame>
        <population>number of participants with evaluable data varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR</title>
            <description>All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Tumour Volume Reduction of at Least ≥ 20% in Extension Phase (FAS)</title>
          <description>Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.</description>
          <population>number of participants with evaluable data varied across visits</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extension Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Absence and Presence of Relevant Disease-related Symptoms (FAS)</title>
        <description>The absence and presence of disease-related symptoms were reported by patients and recorded by the medical staff. Patients classified the symptoms according to a 5-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe</description>
        <time_frame>Baseline and at weeks 4, 12,24,48,72, 96</time_frame>
        <population>number of participants varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Baseline of Main Phase</description>
          </group>
          <group group_id="O2">
            <title>Week 4</title>
            <description>Week 4 of Main Phase</description>
          </group>
          <group group_id="O3">
            <title>Week 12</title>
            <description>Week 12 of Main Phase</description>
          </group>
          <group group_id="O4">
            <title>Week 24</title>
            <description>Week 24 of Main Phase</description>
          </group>
          <group group_id="O5">
            <title>Week 48</title>
            <description>Week 48 of Extension Phase</description>
          </group>
          <group group_id="O6">
            <title>Week 72</title>
            <description>Week 72 of Extension Phase</description>
          </group>
          <group group_id="O7">
            <title>Week 96</title>
            <description>Week 96 of Extension Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Absence and Presence of Relevant Disease-related Symptoms (FAS)</title>
          <description>The absence and presence of disease-related symptoms were reported by patients and recorded by the medical staff. Patients classified the symptoms according to a 5-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe</description>
          <population>number of participants varied across visits</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Headache Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="52.6"/>
                    <measurement group_id="O4" value="45.0"/>
                    <measurement group_id="O5" value="61.5"/>
                    <measurement group_id="O6" value="58.3"/>
                    <measurement group_id="O7" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="36.8"/>
                    <measurement group_id="O4" value="45.0"/>
                    <measurement group_id="O5" value="7.7"/>
                    <measurement group_id="O6" value="8.3"/>
                    <measurement group_id="O7" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="15.0"/>
                    <measurement group_id="O3" value="10.5"/>
                    <measurement group_id="O4" value="10.0"/>
                    <measurement group_id="O5" value="30.8"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visual Disturbances Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="80.0"/>
                    <measurement group_id="O3" value="84.2"/>
                    <measurement group_id="O4" value="85.0"/>
                    <measurement group_id="O5" value="76.9"/>
                    <measurement group_id="O6" value="83.3"/>
                    <measurement group_id="O7" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visual Disturbances Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="10.5"/>
                    <measurement group_id="O4" value="10.0"/>
                    <measurement group_id="O5" value="7.7"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visual Disturbances Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="5.3"/>
                    <measurement group_id="O4" value="5.0"/>
                    <measurement group_id="O5" value="15.4"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visual Disturbances Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="80.0"/>
                    <measurement group_id="O3" value="73.7"/>
                    <measurement group_id="O4" value="75.0"/>
                    <measurement group_id="O5" value="69.2"/>
                    <measurement group_id="O6" value="58.3"/>
                    <measurement group_id="O7" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0"/>
                    <measurement group_id="O2" value="15.0"/>
                    <measurement group_id="O3" value="21.1"/>
                    <measurement group_id="O4" value="20.0"/>
                    <measurement group_id="O5" value="30.8"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5.3"/>
                    <measurement group_id="O4" value="5.0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="8.3"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased libido Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0"/>
                    <measurement group_id="O2" value="65.0"/>
                    <measurement group_id="O3" value="68.4"/>
                    <measurement group_id="O4" value="65.0"/>
                    <measurement group_id="O5" value="61.5"/>
                    <measurement group_id="O6" value="66.7"/>
                    <measurement group_id="O7" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased libido Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="10.5"/>
                    <measurement group_id="O4" value="10.0"/>
                    <measurement group_id="O5" value="23.1"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased libido Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="5.3"/>
                    <measurement group_id="O4" value="10.0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased libido Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="15.0"/>
                    <measurement group_id="O3" value="15.8"/>
                    <measurement group_id="O4" value="15.0"/>
                    <measurement group_id="O5" value="15.4"/>
                    <measurement group_id="O6" value="8.3"/>
                    <measurement group_id="O7" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased libido Very severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erectile dysfunction Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="11.1"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="11.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erectile dysfunction No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8"/>
                    <measurement group_id="O2" value="88.9"/>
                    <measurement group_id="O3" value="88.9"/>
                    <measurement group_id="O4" value="88.9"/>
                    <measurement group_id="O5" value="100.0"/>
                    <measurement group_id="O6" value="100.0"/>
                    <measurement group_id="O7" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regular Menses Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5"/>
                    <measurement group_id="O2" value="55.6"/>
                    <measurement group_id="O3" value="62.5"/>
                    <measurement group_id="O4" value="55.6"/>
                    <measurement group_id="O5" value="60.0"/>
                    <measurement group_id="O6" value="50.0"/>
                    <measurement group_id="O7" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regular Menses No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5"/>
                    <measurement group_id="O2" value="44.4"/>
                    <measurement group_id="O3" value="37.5"/>
                    <measurement group_id="O4" value="44.4"/>
                    <measurement group_id="O5" value="40.0"/>
                    <measurement group_id="O6" value="50.0"/>
                    <measurement group_id="O7" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean GH and IGF-1 Hormone Levels During Main and Extension Phases (FAS)</title>
        <description>Hormone levels, including those of GH, IGF-1, and prolactin were evaluated by a central lab</description>
        <time_frame>Baseline and at weeks 24, 48, 96</time_frame>
        <population>number of participants with evaluable data varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Baseline of Main Phase</description>
          </group>
          <group group_id="O2">
            <title>Week 24</title>
            <description>Week 24 of Main Phase</description>
          </group>
          <group group_id="O3">
            <title>Week 48</title>
            <description>Week 48 of Extension Phase</description>
          </group>
          <group group_id="O4">
            <title>Week 96</title>
            <description>Week 96 of Extension Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Mean GH and IGF-1 Hormone Levels During Main and Extension Phases (FAS)</title>
          <description>Hormone levels, including those of GH, IGF-1, and prolactin were evaluated by a central lab</description>
          <population>number of participants with evaluable data varied across visits</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GH</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.63"/>
                    <measurement group_id="O2" value="1.11" spread="4.10"/>
                    <measurement group_id="O3" value="0.15" spread="0.15"/>
                    <measurement group_id="O4" value="0.12" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGF-1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.73" spread="44.4"/>
                    <measurement group_id="O2" value="72.59" spread="35.55"/>
                    <measurement group_id="O3" value="66.23" spread="31.46"/>
                    <measurement group_id="O4" value="70.82" spread="32.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolactin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.90" spread="12.91"/>
                    <measurement group_id="O2" value="13.89" spread="17.32"/>
                    <measurement group_id="O3" value="9.03" spread="6.27"/>
                    <measurement group_id="O4" value="7.62" spread="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean ACTH and Estradiol Hormone Levels During Main and Extension Phases (FAS)</title>
        <description>Hormone levels, including those of growth hormone (GH),insulin-like growth factor 1 (IGF-1), follicle-stimulating hormone (FSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), prolactin, cortisol, free thyroxine (free T4), and estradiol (for women) or testosterone (for men), were evaluated by a central lab</description>
        <time_frame>Baseline and at weeks 24, 48, 96</time_frame>
        <population>participants with evaluable data varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Baseline of Main Phase</description>
          </group>
          <group group_id="O2">
            <title>Week 24</title>
            <description>Week 24 of Main Phase</description>
          </group>
          <group group_id="O3">
            <title>Week 48</title>
            <description>Week 48 of Extension Phase</description>
          </group>
          <group group_id="O4">
            <title>Week 96</title>
            <description>Week 96 of Extension Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Mean ACTH and Estradiol Hormone Levels During Main and Extension Phases (FAS)</title>
          <description>Hormone levels, including those of growth hormone (GH),insulin-like growth factor 1 (IGF-1), follicle-stimulating hormone (FSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), prolactin, cortisol, free thyroxine (free T4), and estradiol (for women) or testosterone (for men), were evaluated by a central lab</description>
          <population>participants with evaluable data varied across visits</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACTH</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.91" spread="37.07"/>
                    <measurement group_id="O2" value="23.18" spread="31.67"/>
                    <measurement group_id="O3" value="36.06" spread="33.09"/>
                    <measurement group_id="O4" value="29.90" spread="26.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estradiol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.72" spread="21.03"/>
                    <measurement group_id="O2" value="32.12" spread="17.71"/>
                    <measurement group_id="O3" value="34.69" spread="14.74"/>
                    <measurement group_id="O4" value="19.98" spread="15.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Cortisol Hormone Levels During Main and Extension Phases (FAS)</title>
        <description>Hormone levels, including those of GH, IGF-1, follicle-stimulating hormone (FSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), prolactin, cortisol, free T4, and estradiol (for women) or testosterone (for men), were evaluated by a central lab</description>
        <time_frame>Baseline and at weeks 24, 48, 96</time_frame>
        <population>number participants with evaluable data varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Baseline of Main Phase</description>
          </group>
          <group group_id="O2">
            <title>Week 24</title>
            <description>Week 24 of Main Phase</description>
          </group>
          <group group_id="O3">
            <title>Week 48</title>
            <description>Week 48 of Extension Phase</description>
          </group>
          <group group_id="O4">
            <title>Week 96</title>
            <description>Week 96 of Extension Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cortisol Hormone Levels During Main and Extension Phases (FAS)</title>
          <description>Hormone levels, including those of GH, IGF-1, follicle-stimulating hormone (FSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), prolactin, cortisol, free T4, and estradiol (for women) or testosterone (for men), were evaluated by a central lab</description>
          <population>number participants with evaluable data varied across visits</population>
          <units>µg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.60" spread="4.37"/>
                    <measurement group_id="O2" value="16.41" spread="8.28"/>
                    <measurement group_id="O3" value="12.12" spread="4.43"/>
                    <measurement group_id="O4" value="10.09" spread="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean LH and FSH Hormone Levels During Main and Extension Phases (FAS)</title>
        <description>Hormone levels, including those of GH, IGF-1, follicle-stimulating hormone (FSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), prolactin, cortisol, free T4, and estradiol (for women) or testosterone (for men), were evaluated by a central lab</description>
        <time_frame>Baseline and at weeks 24, 48, 96</time_frame>
        <population>participants with evaluable data varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Baseline of Main Phase</description>
          </group>
          <group group_id="O2">
            <title>Week 24</title>
            <description>Week 24 of Main Phase</description>
          </group>
          <group group_id="O3">
            <title>Week 48</title>
            <description>Week 48 of Extension Phase</description>
          </group>
          <group group_id="O4">
            <title>Week 96</title>
            <description>Week 96 of Extension Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Mean LH and FSH Hormone Levels During Main and Extension Phases (FAS)</title>
          <description>Hormone levels, including those of GH, IGF-1, follicle-stimulating hormone (FSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), prolactin, cortisol, free T4, and estradiol (for women) or testosterone (for men), were evaluated by a central lab</description>
          <population>participants with evaluable data varied across visits</population>
          <units>mUI/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LH</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.57" spread="6.91"/>
                    <measurement group_id="O2" value="5.32" spread="7.25"/>
                    <measurement group_id="O3" value="7.44" spread="7.07"/>
                    <measurement group_id="O4" value="9.95" spread="9.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FSH</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.83" spread="18.89"/>
                    <measurement group_id="O2" value="12.90" spread="20.00"/>
                    <measurement group_id="O3" value="16.23" spread="20.97"/>
                    <measurement group_id="O4" value="21.45" spread="24.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Testosterone and Free T4 Hormone Levels During Main and Extension Phases (FAS)</title>
        <description>Hormone levels, including those of GH, IGF-1, follicle-stimulating hormone (FSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), prolactin, cortisol, free T4, and estradiol (for women) or testosterone (for men), were evaluated by a central lab</description>
        <time_frame>Baseline and at weeks 24, 48, 96</time_frame>
        <population>participants with evaluable data varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Baseline of Main Phase</description>
          </group>
          <group group_id="O2">
            <title>Week 24</title>
            <description>Week 24 of Main Phase</description>
          </group>
          <group group_id="O3">
            <title>Week 48</title>
            <description>Week 48 of Extension Phase</description>
          </group>
          <group group_id="O4">
            <title>Week 96</title>
            <description>Week 96 of Extension Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Testosterone and Free T4 Hormone Levels During Main and Extension Phases (FAS)</title>
          <description>Hormone levels, including those of GH, IGF-1, follicle-stimulating hormone (FSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), prolactin, cortisol, free T4, and estradiol (for women) or testosterone (for men), were evaluated by a central lab</description>
          <population>participants with evaluable data varied across visits</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="452.21" spread="214.52"/>
                    <measurement group_id="O2" value="372.72" spread="205.25"/>
                    <measurement group_id="O3" value="517.52" spread="200.64"/>
                    <measurement group_id="O4" value="382.10" spread="179.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free T4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="0.12"/>
                    <measurement group_id="O2" value="1.13" spread="0.18"/>
                    <measurement group_id="O3" value="1.17" spread="0.17"/>
                    <measurement group_id="O4" value="1.04" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean TSH Hormone Levels During Main and Extension Phases (FAS)</title>
        <description>Hormone levels, including those of GH, IGF-1, follicle-stimulating hormone (FSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), prolactin, cortisol, free T4, and estradiol (for women) or testosterone (for men), were evaluated by a central lab</description>
        <time_frame>Baseline and at weeks 24, 48, 96</time_frame>
        <population>participants with evaluable data varied across visits</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Baseline of Main Phase</description>
          </group>
          <group group_id="O2">
            <title>Week 24</title>
            <description>Week 24 of Main Phase</description>
          </group>
          <group group_id="O3">
            <title>Week 48</title>
            <description>Week 48 of Extension Phase</description>
          </group>
          <group group_id="O4">
            <title>Week 96</title>
            <description>Week 96 of Extension Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Mean TSH Hormone Levels During Main and Extension Phases (FAS)</title>
          <description>Hormone levels, including those of GH, IGF-1, follicle-stimulating hormone (FSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), prolactin, cortisol, free T4, and estradiol (for women) or testosterone (for men), were evaluated by a central lab</description>
          <population>participants with evaluable data varied across visits</population>
          <units>µUI/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.81" spread="655.82"/>
                    <measurement group_id="O2" value="149.92" spread="628.93"/>
                    <measurement group_id="O3" value="1.67" spread="1.27"/>
                    <measurement group_id="O4" value="1.70" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Alpha Subunit Levels in Main and Extension Phases (FAS)</title>
        <time_frame>Baseline and at weeks 12,24,48,72, 96</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Baseline of Main Phase</description>
          </group>
          <group group_id="O2">
            <title>Week 12</title>
            <description>Week 12 of Main Phase</description>
          </group>
          <group group_id="O3">
            <title>Week 24</title>
            <description>Week 24 of Main Phase</description>
          </group>
          <group group_id="O4">
            <title>Week 48</title>
            <description>Week 48 of Extension Phase</description>
          </group>
          <group group_id="O5">
            <title>Week 72</title>
            <description>Week 72 of Extension Phase</description>
          </group>
          <group group_id="O6">
            <title>Week 96</title>
            <description>Week 96 of Extension Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Alpha Subunit Levels in Main and Extension Phases (FAS)</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242.27" spread="286.90"/>
                    <measurement group_id="O2" value="309.04" spread="270.52"/>
                    <measurement group_id="O3" value="192.11" spread="201.25"/>
                    <measurement group_id="O4" value="234.21" spread="182.59"/>
                    <measurement group_id="O5" value="286.78" spread="288.62"/>
                    <measurement group_id="O6" value="435.00" spread="310.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Reduction From Baseline of Alpha Subunit ≥50% in Main and Extension Phases (FAS)</title>
        <description>Alpha subunit levels were determined at a central laboratory.</description>
        <time_frame>Baseline up to approximately Week 96</time_frame>
        <population>Evaluable participants had to have 50% reduction</population>
        <group_list>
          <group group_id="O1">
            <title>Week 12</title>
            <description>Week 12 of Main Phase</description>
          </group>
          <group group_id="O2">
            <title>Week 24</title>
            <description>Week 24 of Main Phase</description>
          </group>
          <group group_id="O3">
            <title>Week 48</title>
            <description>Week 48 of Extension Phase</description>
          </group>
          <group group_id="O4">
            <title>Week 72</title>
            <description>Week 72 of Extension Phase</description>
          </group>
          <group group_id="O5">
            <title>Week 96</title>
            <description>Week 96 of Extension Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Reduction From Baseline of Alpha Subunit ≥50% in Main and Extension Phases (FAS)</title>
          <description>Alpha subunit levels were determined at a central laboratory.</description>
          <population>Evaluable participants had to have 50% reduction</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="12.5"/>
                    <measurement group_id="O4" value="22.2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 104 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pasireotide LAR</title>
          <description>All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

